H. Lundbeck A/s

This study tests whether eptinezumab, given through a vein, can safely reduce the number of migraine days in children and teens aged 6 to 17 with episodic migraine. Participants receive either the drug or a placebo, and researchers track monthly migraine days over 12 weeks. The g…

This study tests whether eptinezumab, given as an IV infusion, can reduce the number of migraine days in adolescents aged 12 to 17 who have chronic migraine (15 or more headache days per month). Participants will receive either the drug or a placebo (salt water) and track their h…

This study tests a new drug called Lu AG13909 in 18 adults with Cushing's disease, a rare condition where the body produces too much cortisol. The goal is to see if the drug can safely lower cortisol levels to normal. Participants will receive the drug through an IV or injection,…

This study tests the long-term safety of eptinezumab (Vyepti) in 600 children and teens aged 6 to 17 with chronic or episodic migraine. Participants must have completed a prior study. The main goal is to track side effects over time, with additional measures of drug levels and im…

This early-stage trial is testing a new drug called Lu AG13909 in 42 adults with congenital adrenal hyperplasia (CAH), a rare genetic condition that disrupts hormone production. The study aims to check the drug's safety, how it moves through the body, and its effects on hormone l…

This early-stage trial is testing a new drug called Lu AH69593 to see if it is safe and how the body handles it. The study includes healthy volunteers and people with narcolepsy. Researchers will monitor side effects and measure drug levels in the blood, including how food affect…